NATCO Pharma shares jumped more than 3% in morning trade after the company announced that Mylan Pharmaceuticals Inc. and Novo Nordisk had settled a U.S. patent litigation concerning developing a generic version of Ozempic (Semaglutide).
The settlement details will remain confidential. NATCO Pharma and Mylan are working together to develop a generic version of Ozempic, a popular treatment for Type 2 diabetes.
As of 9:25 am, NATCO Pharma shares were trading 3.61% higher at Rs 1,402.80 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
